T. Rowe Price Investment Management, Inc. Vaxcyte, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $163 Billion
- Q1 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 3,552,967 shares of PCVX stock, worth $276 Million. This represents 0.15% of its overall portfolio holdings.
Number of Shares
3,552,967
Previous 1,246,041
185.14%
Holding current value
$276 Million
Previous $78.3 Million
210.16%
% of portfolio
0.15%
Previous 0.05%
Shares
6 transactions
Others Institutions Holding PCVX
# of Institutions
268Shares Held
97.1MCall Options Held
202KPut Options Held
147K-
Vanguard Group Inc Valley Forge, PA9.74MShares$757 Million0.01% of portfolio
-
Black Rock Inc. New York, NY9.51MShares$740 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X07.67MShares$597 Million0.29% of portfolio
-
Wellington Management Group LLP Boston, MA4.92MShares$383 Million0.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.14MShares$322 Million0.07% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $4.61B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...